Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Nektar, BMS terminate combo’s development after another pair of misses

Failures in renal, bladder cancers closely follow Phase III miss for bempegaldesleukin plus Opdivo in first-line melanoma 

April 14, 2022 10:56 PM UTC

The failure of Nektar’s IL-2 program in two more clinical trials extinguishes hopes for a four-year-old partnership in which BMS paid $1 billion up front to explore combinations with oncology blockbuster Opdivo.

Nektar Therapeutics (NASDAQ:NKTR) said late Thursday that bempegaldesleukin plus PD-1 inhibitor Opdivo nivolumab from  Bristol Myers Squibb Co. (NYSE:BMY) did not meet criteria to show clinical benefit compared with the control arm in the Phase III PIVOT-09 study as first-line therapy for renal cell carcinoma...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article